{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:11:42Z","timestamp":1771002702729,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["No.201803D31139"],"award-info":[{"award-number":["No.201803D31139"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:sup>99m<\/jats:sup>Tc-Rituximab is a new specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells. We conducted a study in which <jats:sup>99m<\/jats:sup>Tc-Rituximab was compared with filtered <jats:sup>99m<\/jats:sup>Tc-sulfur colloid (fTcSC) for sentinel lymph node (SLN) detection in patients with breast cancer.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>The study is divided into three parts. 1. Initially, 25 patients were selected for an internal controlled trial to received both <jats:sup>99m<\/jats:sup>Tc-Rituximab and fTcSC, the interval time is separated by \u22652\u2009days. 2. Then, 91 patients were selected for a randomized controlled trial (41 and 50 patients in the <jats:sup>99m<\/jats:sup>Tc-Rituximab and fTcSC groups, respectively). All patients were administered either agent at the 6- and 12-o\u2019 clock positions by subareolar injection technique. SLN mapping was then performed 2\u2009h after injection. 3. Serial dynamic images were further acquired for 2\u2009h in 31 patients (22 and 9 patients from <jats:sup>99m<\/jats:sup>Tc-Rituximab and fTcSC cohorts, respectively).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The identification rate of lymphoscintigraphy and SLNB in all and axilla regions for <jats:sup>99m<\/jats:sup>Tc-Rituximab and <jats:sup>99m<\/jats:sup>Tc-SC were 98.5% vs 98.7, 100% vs 98.4%, respectively. The mean number of SLNs identified by <jats:sup>99m<\/jats:sup>Tc-Rituximab and fTcSC was respectively 2.72 and 3.28, with a significant difference of <jats:italic>P<\/jats:italic>\u00a0=\u20090.013 (paired sample t-test). The difference exists in the internal mammary and clavicular area, not in the axillary. The mean number of axillary sentinel lymph node biopsy (SLNB) for <jats:sup>99m<\/jats:sup>Tc-Rituximab and fTcSC was 2.95 vs 3.14, respectively, and no significant difference existed. <jats:sup>99m<\/jats:sup>Tc-Rituximab also exhibited a significantly faster injection site clearance rate when compared with fTcSC (0.193\u2009\u00b1\u00a00.057\u2009h<jats:sup>\u2212\u20091<\/jats:sup> vs 0.021\u2009\u00b1\u00a00.007\u2009h<jats:sup>\u2212\u20091<\/jats:sup>, respectively).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>No significant difference was observed in identification rate and number of axillary SLN imaging and SLNB, between the two tracers. Compared to fTcSC, <jats:sup>99m<\/jats:sup>Tc-Rituximab based imaging demonstrated a fewer number of secondary lymph nodes and had faster injection site clearance rate.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>www.chictr.org.cn, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/listbycreater.aspx\">ChiCTR1900024990<\/jats:ext-link> (retrospectively registered August 6, 2019).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6197-9","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:47:42Z","timestamp":1571143662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Jing-Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Xia","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"issue":"2","key":"6197_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I","volume":"39","author":"RM Cabanas","year":"1977","unstructured":"Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39(2):456\u201366.","journal-title":"Cancer"},{"issue":"10","key":"6197_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):908\u20139.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6197_CR3","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1007\/PL00014793","volume":"26","author":"AJ Wilhelm","year":"1999","unstructured":"Wilhelm AJ, Mijnhout GS, Franssen EJF. Radiopharmaceuticals in sentinel lymph-node detection - an overview. Eur J Nucl Med. 1999;26(1):S36\u201342.","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"6197_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1245\/ASO.2003.07.012","volume":"10","author":"AM Wallace","year":"2003","unstructured":"Wallace AM, Hoh CK, Vera DR, et al. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10(5):531\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6197_CR5","first-page":"951","volume":"42","author":"DR Vera","year":"2001","unstructured":"Vera DR, Wallace AM, Hoh CK, et al. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran. J Nucl Med. 2001;42(6):951\u20139.","journal-title":"J Nucl Med"},{"key":"6197_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140\u201374.","journal-title":"Curr Dir Autoimmun"},{"issue":"25","key":"6197_CR7","doi-asserted-by":"crossref","first-page":"38810","DOI":"10.18632\/oncotarget.9614","volume":"7","author":"X Wang","year":"2016","unstructured":"Wang X, Yang Z, Lin B, et al. Technetium-99m-labeled rituximab for use as a specific tracer of sentinel lymph node biopsy: a translational research study. Oncotarget. 2016;7(25):38810\u201321.","journal-title":"Oncotarget"},{"issue":"6","key":"6197_CR8","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00259-013-2544-2","volume":"41","author":"F Giammarile","year":"2013","unstructured":"Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med. 2013;41(6):1932\u201347.","journal-title":"Eur J Nucl Med"},{"issue":"8","key":"6197_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2967\/jnumed.115.160572","volume":"57","author":"N Li","year":"2016","unstructured":"Li N, Wang X, Lin B, et al. Clinical evaluation of 99mTc-rituximab for sentinel lymph node mapping in breast Cancer patients. J Nucl Med. 2016;57(8):1214\u201320.","journal-title":"J Nucl Med"},{"issue":"2","key":"6197_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1067\/msy.2000.108064","volume":"128","author":"RC Martin","year":"2000","unstructured":"Martin RC, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. Surgery. 2000;128(2):139\u201344.","journal-title":"Surgery"},{"issue":"4","key":"6197_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","volume":"13","author":"LG Wilke","year":"2006","unstructured":"Wilke LG, Mccall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491\u2013500.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6197_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4143\/crt.2018.062","volume":"51","author":"XS Cao","year":"2019","unstructured":"Cao XS, Yang GR, Cong B, et al. The lymphatic drainage pattern of internal mammary sentinel lymph node identified by small particle radiotracer (99mTc-dextran 40) in breast. Cancer Res Treat. 2019;51(2):483\u201392.","journal-title":"Cancer Res Treat"},{"issue":"8","key":"6197_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.nucmedbio.2003.10.001","volume":"30","author":"SJ Ellner","year":"2003","unstructured":"Ellner SJ, Hoh CK, Vera DR, et al. Dose-dependent biodistribution of [99mTc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol. 2003;30(8):805\u201310.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"6197_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/radiol.12120638","volume":"265","author":"DK Emerson","year":"2012","unstructured":"Emerson DK, Limmer K, Hall DJ, et al. A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging. Radiology. 2012;265(1):186\u201393.","journal-title":"Radiology"},{"issue":"13","key":"6197_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","volume":"32","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast Cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365\u201383.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6197_CR16","first-page":"381","volume":"18","author":"AB Chagpar","year":"2008","unstructured":"Chagpar AB, Scoggins CR, Martin RCG, et al. Are 3 Sentinel Nodes Sufficient? Breast Dis. 2008;18(4):381\u20132.","journal-title":"Breast Dis"},{"issue":"1","key":"6197_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cncr.23514","volume":"113","author":"M Yi","year":"2008","unstructured":"Yi M, Mericbernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113(1):30\u20137.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6197-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:20:19Z","timestamp":1602631219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6197"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6197-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"13 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Shanxi DaYi Hospital institutional review board (China). All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"956"}}